Study identifier:4522US/0003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 12-week, Randomized, Open-Label, 3 Arm Parallel group, Multicenter, Phase IIIb Study comparing the efficacy and safety of Rosuvastatin with Atorvastatin and Simvastatin Achieving NCEP ATP III LDL-C Goals in high risk subjects with Hypercholesterolaemia in the Managed Care Setting.
Hypercholesterolemia
Phase 3
No
Rosuvastatin, Simvastatin, Atorvastatin
All
4444
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 Rosuvastatin | - |
Active Comparator: 2 Simvastatin | - |
Active Comparator: 3 Atorvastatin | - |